The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETs.

CONCLUSION: Second-line ET might be a viable treatment option for postmenopausal patients with MBC with low and very low sensitivity to initial ET. Future studies based on larger and independent cohorts are needed to validate these findings.
PMID: 32394413 [PubMed - as supplied by publisher]

Source: Breast Cancer - May 10, 2020 Category: Cancer & Oncology Authors: Iwamoto T, Fujisawa T, Shien T, Araki K, Sakamaki K, Sangai T, Kikawa Y, Takao S, Nishimura R, Takahashi M, Aihara T, Mukai H, Taira N Tags: Breast Cancer Source Type: research